Back to Search
Start Over
Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.
- Source :
-
BMC cancer [BMC Cancer] 2018 Jul 31; Vol. 18 (1), pp. 775. Date of Electronic Publication: 2018 Jul 31. - Publication Year :
- 2018
-
Abstract
- Background: The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic cyclophosphamide (OMC).<br />Methods: Patients ≥ 18 years of age with refractory metastatic cancers were eligible if no standard curative measures existed. Paclitaxel was administered IV weekly (D1, D8, D15; D1 = D28) in combination with a fixed dose of OMC (50 mg twice a day). A 3 + 3 design was used for dose escalation of wP (40 to 75 mg/m <superscript>2</superscript> ) followed by an expansion cohort at RP2D. Dose-limiting toxicity (DLT) was defined over the first 28-day cycle as grade ≥ 3 non-hematological or grade 4 hematological toxicity (NCI-CTCAE v4.0) or any toxicity leading to a dose reduction.<br />Results: In total, 28 pts. (18 in dose-escalation phase and 10 in expansion cohort) were included, and 16/18 pts. enrolled in the dose-escalation phase were evaluable for DLT. DLT occurred in 0/3, 1/6 (neuropathy), 0/3 and 2/4 pts. (hematological toxicity) at doses of 40, 60, 70 and 75 mg/m <superscript>2</superscript> of wP, respectively. The RP2D of wP was 70 mg/m <superscript>2</superscript> ; 1/10 patients in the expansion phase had a hematological DLT. At RP2D (n = 14), the maximal grade of drug-related adverse event was Gr1 in three patients, Gr2 in six patients, Gr3 in one patient and Gr4 in one patient (no AE in three patients). At RP2D, a partial response was observed in one patient with lung adenocarcinoma.<br />Conclusion: The combination of OMC and wP resulted in an acceptable safety profile, warranting further clinical evaluation.<br />Trial Registration: TRN: NCT01374620 ; date of registration: 16 June 2011.
- Subjects :
- Administration, Metronomic
Administration, Oral
Adolescent
Adult
Aged
Antineoplastic Agents adverse effects
Antineoplastic Agents therapeutic use
Cyclophosphamide adverse effects
Cyclophosphamide therapeutic use
Humans
Middle Aged
Paclitaxel adverse effects
Paclitaxel therapeutic use
Young Adult
Antineoplastic Agents administration & dosage
Cyclophosphamide administration & dosage
Neoplasms drug therapy
Paclitaxel administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2407
- Volume :
- 18
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30064401
- Full Text :
- https://doi.org/10.1186/s12885-018-4678-x